| Peer-Reviewed

An Analytical Procedure by the Inductively Coupled Plasma Mass Spectrometry (ICP-MS) for the Quantitation of Total Phosphorus Content on the Surface of the Manufacturing Equipment for Oligonucleotides

Received: 25 December 2019     Accepted: 7 January 2020     Published: 30 January 2020
Views:       Downloads:
Abstract

An analytical procedure by the inductively coupled plasma mass spectrometry (ICP-MS) is provided to quantitate the remaining phosphorus amount on the surface of the manufacturing equipment for the oligonucleotide active pharmaceutical ingredient (API). In this analytical procedure, the sample solutions obtained from the rinse sampling and direct surface sampling methods are directly injected into the ICP-MS equipment without the inspissation of the extraction liquid. The limit of quantitation for phosphorous was 0.02 µg/mL. Quantitation of phosphorous was achieved over a linear range of 0.02 to 0.8 µg/mL. Analytical validation was carried out to prove that this analytical procedure is appropriate and effective to monitor the cleanliness of the manufacturing equipment after the oligonucleotide API manufacturing and the following cleaning of the equipment. Calibration curve originally passed through the origin with correlation coefficient of 0.999. The precision through the rinse sampling method was within ±10%. The satisfactory accuracy for the rinse sampling method was proven from the assessment of linearity and precision. The precision and accuracy of the analytical procedure were both within ±10% for the direct surface sampling method. The described analytical procedure by ICP-MS following the two types of the sampling procedures can easily be applied to the routine analysis for the verification of the cleanliness of the manufacturing equipment for oligonucleotide API.

Published in Science Journal of Analytical Chemistry (Volume 8, Issue 1)
DOI 10.11648/j.sjac.20200801.11
Page(s) 1-4
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2020. Published by Science Publishing Group

Keywords

ICP-MS, Oligonucleotide, Validation, Sampling, Manufacture, Cleanliness

References
[1] S. Crooke, Antisense Nucleic Acid Drug Dev. 8 (2) (1998) 133.
[2] S. Crooke, Vitravene – another piece in the mosaic, Antisense Nucleic Acid Drug Dev. 8 (4) (1998) (vii-viii).
[3] T. Abe, T. Mizuta, T. Hatta, N. Miyano-Kurosaki, M. Fujiwara, K. Takai, S. Shigeta, T. Yokota, H. Takaku, Antisense therapy of influenza, Eur. J. Pharm. Sci. 13 (2001) 61–69.
[4] N. Dias, C. A. Stein, Antisense oligonucleotides: basic concepts and mechanisms, Mol. Cancer Ther. 1 (2002) 347–355.
[5] N. M. Dean, F. Bennett, Antisense oligonucleotide-based therapeutics for cancer, Oncogene 22 (2003) 9087–9096.
[6] C. Mello, D. Conte, Revealing the world of RNA interference, Nature 431 (2004) 338–342.
[7] D. P. Bartel, MicroRNAs: genomics, biogenesis, mechanism, and function, Cell 116 (2004) 281–297.
[8] S. Doggrell, Expert Opin. Pharmacother. 6 (8) (2005) 1421.
[9] S. Doggrell, Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration, Expert Opin. Pharmacother. 6 (8) (2005) 1421–1423.
[10] S. T. Crooke, An overview of progress in antisense therapeutics, Antisense Nucleic Acid Drug Dev. 8 (2) (2009) 115–122.
[11] A. C. McGinnis, B. Chen, M. G. Bartlett, Chromatographic methods for the determination of therapeutic Oligonucleotides, J. Chromatogr. B 883 (2012) 76–94.
[12] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, GOOD MANUFACTURING PRACTICE GUIDE FOR ACTIVE PHARMACEUTICAL INGREDIENTS Q7, 2000. https://www.pmda.go.jp/files/00.026709.pdf.
[13] C Diane Beauchemin, Inductively Coupled Plasma Mass spectroscopy, Anal. Chem., 2010, 82, 12, 4786-4810.
[14] D R. S. Houk., Mass spectrometry of inductively coupled plasmas, Anal. Chem., 1986, 58, 1, 97A-105A.
[15] E Scott C Wilschefski, Matthew R Baxter, Inductively Coupled Plasma Mass Spectrometry: Introduction to Analytical Aspects, Clin Biochem Rev., 2019 Aug; 40 (3): 115–133.
[16] Jeffrey R. Bacon, Jeffrey S. Crain, Luc Van Vaeck and John G. Williams, Atomic mass spectrometry, Journal of Analytical Atomic Spectrometry, 14 (10), 1633-1659.
[17] Pharmacopoeia of the United States of America (USP).
[18] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY Q2 (R1), 2005. https://www.pmda.go.jp/files/00.026867.pdf.
[19] D. Pro¨ frock, P. Leonhard, A. Prange. ‘‘Determination of phosphorus in phosphorylated deoxyribonucleotides using capillary electrophoresis and high performance liquid chromatography hyphenated to inductively coupled plasma mass spectrometry with an octopole reaction cell’’. J. Anal. At. Spectrom. 2003. 18 (7): 708-713.
[20] M. Edler, N. Jakubowski, M. Linscheid. ‘‘Quantitative determination of melphalan DNA adducts using HPLC – inductively coupled mass spectrometry’’. J. Mass. Spectrom. 2006. 41 (4): 507-516.
[21] D. G. Sar, L. Aguado, M. M. Bayon, M. A. Comendador, E. B. Gonzalez, A. Sanz-Medel, L. M. Sierra. ‘‘Relationships between cisplatin-induced adducts and DNA strandbreaks, mutation and recombination in vivo in somatic cells of Drosophila melanogaster, under different conditions of nucleotide excision repair’’. Mutation Research-Genetic Toxicology and Environmental Mutagenesis. 2012. 741 (1-2): 81-88.
[22] L. L. Fernandez, M. Montes-Bayon, E. B. Gonzalez, L. M. Sierra, A. Sanz-Medel, J. Bettmer. ‘‘Initial studies on quantitative DNA induced oxidation by gel electrophoresis (GE)-ICP-MS’’. J. Anal. At. Spectrom. 2011. 26 (1): 195-200.
[23] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, ASSESSMENT AND CONTROL OF DNA REACTIVE (MUTAGENIC) IMPURITIES IN PHARMACEUTICALS TO LIMIT POTENTIAL CARCINOGENIC RISK M7 (R1), 2017. http://www.pmda.go.jp/files/000218750.pdf.
Cite This Article
  • APA Style

    Daisuke Furukawa, Masami Nakai, Masato Kazusaki. (2020). An Analytical Procedure by the Inductively Coupled Plasma Mass Spectrometry (ICP-MS) for the Quantitation of Total Phosphorus Content on the Surface of the Manufacturing Equipment for Oligonucleotides. Science Journal of Analytical Chemistry, 8(1), 1-4. https://doi.org/10.11648/j.sjac.20200801.11

    Copy | Download

    ACS Style

    Daisuke Furukawa; Masami Nakai; Masato Kazusaki. An Analytical Procedure by the Inductively Coupled Plasma Mass Spectrometry (ICP-MS) for the Quantitation of Total Phosphorus Content on the Surface of the Manufacturing Equipment for Oligonucleotides. Sci. J. Anal. Chem. 2020, 8(1), 1-4. doi: 10.11648/j.sjac.20200801.11

    Copy | Download

    AMA Style

    Daisuke Furukawa, Masami Nakai, Masato Kazusaki. An Analytical Procedure by the Inductively Coupled Plasma Mass Spectrometry (ICP-MS) for the Quantitation of Total Phosphorus Content on the Surface of the Manufacturing Equipment for Oligonucleotides. Sci J Anal Chem. 2020;8(1):1-4. doi: 10.11648/j.sjac.20200801.11

    Copy | Download

  • @article{10.11648/j.sjac.20200801.11,
      author = {Daisuke Furukawa and Masami Nakai and Masato Kazusaki},
      title = {An Analytical Procedure by the Inductively Coupled Plasma Mass Spectrometry (ICP-MS) for the Quantitation of Total Phosphorus Content on the Surface of the Manufacturing Equipment for Oligonucleotides},
      journal = {Science Journal of Analytical Chemistry},
      volume = {8},
      number = {1},
      pages = {1-4},
      doi = {10.11648/j.sjac.20200801.11},
      url = {https://doi.org/10.11648/j.sjac.20200801.11},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.sjac.20200801.11},
      abstract = {An analytical procedure by the inductively coupled plasma mass spectrometry (ICP-MS) is provided to quantitate the remaining phosphorus amount on the surface of the manufacturing equipment for the oligonucleotide active pharmaceutical ingredient (API). In this analytical procedure, the sample solutions obtained from the rinse sampling and direct surface sampling methods are directly injected into the ICP-MS equipment without the inspissation of the extraction liquid. The limit of quantitation for phosphorous was 0.02 µg/mL. Quantitation of phosphorous was achieved over a linear range of 0.02 to 0.8 µg/mL. Analytical validation was carried out to prove that this analytical procedure is appropriate and effective to monitor the cleanliness of the manufacturing equipment after the oligonucleotide API manufacturing and the following cleaning of the equipment. Calibration curve originally passed through the origin with correlation coefficient of 0.999. The precision through the rinse sampling method was within ±10%. The satisfactory accuracy for the rinse sampling method was proven from the assessment of linearity and precision. The precision and accuracy of the analytical procedure were both within ±10% for the direct surface sampling method. The described analytical procedure by ICP-MS following the two types of the sampling procedures can easily be applied to the routine analysis for the verification of the cleanliness of the manufacturing equipment for oligonucleotide API.},
     year = {2020}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - An Analytical Procedure by the Inductively Coupled Plasma Mass Spectrometry (ICP-MS) for the Quantitation of Total Phosphorus Content on the Surface of the Manufacturing Equipment for Oligonucleotides
    AU  - Daisuke Furukawa
    AU  - Masami Nakai
    AU  - Masato Kazusaki
    Y1  - 2020/01/30
    PY  - 2020
    N1  - https://doi.org/10.11648/j.sjac.20200801.11
    DO  - 10.11648/j.sjac.20200801.11
    T2  - Science Journal of Analytical Chemistry
    JF  - Science Journal of Analytical Chemistry
    JO  - Science Journal of Analytical Chemistry
    SP  - 1
    EP  - 4
    PB  - Science Publishing Group
    SN  - 2376-8053
    UR  - https://doi.org/10.11648/j.sjac.20200801.11
    AB  - An analytical procedure by the inductively coupled plasma mass spectrometry (ICP-MS) is provided to quantitate the remaining phosphorus amount on the surface of the manufacturing equipment for the oligonucleotide active pharmaceutical ingredient (API). In this analytical procedure, the sample solutions obtained from the rinse sampling and direct surface sampling methods are directly injected into the ICP-MS equipment without the inspissation of the extraction liquid. The limit of quantitation for phosphorous was 0.02 µg/mL. Quantitation of phosphorous was achieved over a linear range of 0.02 to 0.8 µg/mL. Analytical validation was carried out to prove that this analytical procedure is appropriate and effective to monitor the cleanliness of the manufacturing equipment after the oligonucleotide API manufacturing and the following cleaning of the equipment. Calibration curve originally passed through the origin with correlation coefficient of 0.999. The precision through the rinse sampling method was within ±10%. The satisfactory accuracy for the rinse sampling method was proven from the assessment of linearity and precision. The precision and accuracy of the analytical procedure were both within ±10% for the direct surface sampling method. The described analytical procedure by ICP-MS following the two types of the sampling procedures can easily be applied to the routine analysis for the verification of the cleanliness of the manufacturing equipment for oligonucleotide API.
    VL  - 8
    IS  - 1
    ER  - 

    Copy | Download

Author Information
  • Quality Assurance Office Health & Crop Science Sector, Sumitomo Chemical Co., Ltd., Osaka, Japan

  • Quality Assurance Office Health & Crop Science Sector, Sumitomo Chemical Co., Ltd., Osaka, Japan

  • Quality Assurance Office Health & Crop Science Sector, Sumitomo Chemical Co., Ltd., Osaka, Japan

  • Sections